Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
PepGen’s $108 Million Initial Public Offering
Sweetgreen’s Acquisition of Spyce
Goodwin Procter advised Spyce on the deal. sweetgreen, the mission-driven brand serving healthy food at scale, announced its plans to acquire Spyce, the Boston-based restaurant company powered...